Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by
Liaoran Niu1, Xiaoyu Kang2, Jianyong Zheng3
1State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi, PR China; Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi, PR China.
Abstract:
Gastric cancer remains a formidable global health challenge, with drug resistance being a primary contributor to its high mortality rates. Therefore, understanding the mechanisms driving drug resistance is crucial for developing more effective therapeutic interventions. Utilizing high content screening technology, we identified let-7e-5p and miR-125a-5p as the key regulators of drug resistance in GC, both being members of the miR-99b cluster. Findings from GC cells, organoids and PDX models demonstrated that overexpression of the miR-99b cluster sensitized GC to cisplatin, likely through its inhibitory effects on mitochondrial respiratory function, particularly OXPHOS. We further demonstrated that multiple components, especially SDHC subunit of respiratory complex II, were regulated by miR-99b cluster and played critical roles in GC chemoresistance. Then, through a comprehensive screen of epigenetic compounds, we identified KMT5A as a key upstream repressor of the miR-99b cluster in GC, which reinforces the H4K20me1 modification within the miR-99b cluster region. Moreover, elevated KMT5A expression and decreased miR-125a-5p expression indicated both poorer prognosis and chemo-resistance in patients with GC. This study highlights the multifaceted roles of the miR-99b cluster in GC and offers novel perspectives for the development of innovative therapeutics aimed at overcoming chemoresistance and enhancing treatment efficacy for GC patients.
Insights
Gastric cancer drug resistance is a major challenge. The miR-99b cluster sensitizes cancer to cisplatin by impacting mitochondrial respiration, offering new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gastric cancer (GC) poses a significant global health threat, with drug resistance driving high mortality rates.
- Understanding the molecular mechanisms of GC drug resistance is critical for developing effective treatments.
Purpose of the Study:
- To identify key regulators of drug resistance in gastric cancer.
- To elucidate the role of the miR-99b cluster in chemoresistance and its therapeutic potential.
Main Methods:
- High content screening to identify microRNAs involved in drug resistance.
- Utilizing gastric cancer cell lines, organoids, and patient-derived xenograft (PDX) models.
- Investigating the epigenetic regulation of the miR-99b cluster using epigenetic compounds.
Main Results:
- let-7e-5p and miR-125a-5p, members of the miR-99b cluster, were identified as key regulators of GC drug resistance.
- Overexpression of the miR-99b cluster sensitized GC to cisplatin by inhibiting mitochondrial oxidative phosphorylation (OXPHOS), involving the SDHC subunit.
- KMT5A was identified as an upstream repressor of the miR-99b cluster, with elevated KMT5A and decreased miR-125a-5p correlating with poor prognosis and chemoresistance in GC patients.
Conclusions:
- The miR-99b cluster plays a crucial role in regulating gastric cancer chemoresistance.
- Targeting the miR-99b cluster and its regulators presents a promising therapeutic strategy to overcome drug resistance in gastric cancer.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Drugs that Stabilize Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules

